Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma

Trial Profile

A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorine-18 FAPI 74 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Diagnostic use; Registrational
  • Acronyms FAPI-PRO
  • Sponsors SOFIE

Most Recent Events

  • 18 Nov 2025 Planned initiation date changed from 15 Dec 2025 to 23 Dec 2025.
  • 21 Oct 2025 New trial record
  • 01 Oct 2025 According to a SOFIE Biosciences media release, company Alignment with FDA on study design to advance two Phase 3 Clinical trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F]FAPI-74.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top